Advanced in Bladder Reconstruction

Dr. Seth P. Lerner

Urology | Oncology
Baylor College Of Medicine
7200 Cambridge St, 
Houston, TX 
Accepting New Patients
Offers Telehealth
Advanced in Bladder Reconstruction
Baylor College Of Medicine
7200 Cambridge St, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Seth Lerner is an Urologist and an Oncologist in Houston, Texas. Dr. Lerner is rated as an Advanced provider by MediFind in Bladder Reconstruction. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

His clinical research consists of co-authoring 201 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Bladder Reconstruction.

Specialties
Urology
Oncology
Licenses
Urology in TX
Hospital Affiliations
Baylor St Lukes Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

BAYLOR COLLEGE OF MEDICINE
7200 Cambridge St, Houston, TX 77030
Other Locations
BAYLOR COLLEGE OF MEDICINE
6770 Bertner Ave, Suite C 350, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Behavioral
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Other, Biological
Study Drugs: CG0070, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses
Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Biological
Study Drug: Bacillus of Calmette-Guerin Vaccine
Study Phase: Phase 4
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)
Enrollment Status: Terminated
Publish Date: August 24, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

199 Total Publications

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
Journal: The New England journal of medicine
Published: November 26, 2024
Similar Doctors
Advanced in Bladder Reconstruction
Dr. Rose Khavari
Urology
Advanced in Bladder Reconstruction
Dr. Rose Khavari
Urology

Tmh Physician Associates PLLC

6560 Fannin St, Suite 2100, 
Houston, TX 
 (0.8 miles away)
713-441-6455
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rose Khavari is an Urologist in Houston, Texas. Dr. Khavari is rated as a Distinguished provider by MediFind in Bladder Reconstruction. Her top areas of expertise are Neurogenic Bladder, Urinary Incontinence, Stress Urinary Incontinence, Bladder Reconstruction, and Reconstructive Urology Surgery. Dr. Khavari is currently accepting new patients.

Experienced in Bladder Reconstruction
Dr. Monty A. Aghazadeh
Urology | General Surgery
Experienced in Bladder Reconstruction
Dr. Monty A. Aghazadeh
Urology | General Surgery

Tmh Physician Associates PLLC

4710 Bellaire Blvd, 
Bellaire, TX 
 (4.0 miles away)
713-363-9411
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Monty Aghazadeh is an Urologist and a General Surgeon in Bellaire, Texas. Dr. Aghazadeh is rated as an Advanced provider by MediFind in Bladder Reconstruction. His top areas of expertise are Urinary Tract Infection in Children, Cellulitis, Obstructive Uropathy, Ureteroscopy, and Cystectomy. Dr. Aghazadeh is currently accepting new patients.

Experienced in Bladder Reconstruction
Dr. Oluwarotimi S. Nettey
Urology
Experienced in Bladder Reconstruction
Dr. Oluwarotimi S. Nettey
Urology

Baylor College Of Medicine

1504 Taub Loop, 
Houston, TX 
 (0.8 miles away)
713-873-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Oluwarotimi Nettey is an Urologist in Houston, Texas. Dr. Nettey is rated as an Experienced provider by MediFind in Bladder Reconstruction. Her top areas of expertise are Neurogenic Bladder, Prostate Cancer, Urinary Incontinence, Bladder Reconstruction, and Reconstructive Urology Surgery. Dr. Nettey is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lerner's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile